CPX-351 in Myeloid Leukemia of Down Syndrome
We are pleased to highlight a new publication in Blood presenting results from the phase III ML-DS 2018 trial, investigating the use of CPX-351 in children with Down syndrome–associated myeloid leukemia (ML-DS).
Children with ML-DS generally have an excellent prognosis but face a significantly higher risk of treatment-related toxicity. The ML-DS 2018 trial aimed to evaluate whether CPX-351, a liposomal formulation of cytarabine and daunorubicin, could maintain high survival rates while reducing treatment burden.
The study shows that while CPX-351 demonstrated favorable tolerability and no increase in treatment-related mortality, event-free survival was lower compared to standard induction therapy. At the same time, overall survival remained comparable, highlighting the effectiveness of current relapse and salvage strategies.
These findings underline the complexity of balancing efficacy and toxicity in this particularly vulnerable patient group and provide important guidance for future treatment optimization in ML-DS.
We warmly congratulate all investigators and collaborators involved in this important international study.
This phase III ML-DS 2018 trial evaluated the use of CPX-351 in children with Down syndrome–associated myeloid leukemia. While the treatment showed a favorable tolerability profile and overall survival remained comparable to standard therapy, event-free survival was lower. The findings highlight the ongoing challenge of balancing reduced treatment toxicity with maintaining optimal efficacy in this particularly vulnerable patient population.